Prot #263CS201: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/10/20 → 2/10/23

Funding

  • Quintiles, Inc. (Prot #263CS201)
  • Biogen MA Inc. (Prot #263CS201)